
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio Inc. is positioning itself positively in the biopharmaceutical sector with its innovative RNA editing drug, KRRO-121, which targets liver conditions by stabilizing glutamine synthetase and improving ammonia clearance, thus addressing significant unmet medical needs. The company has demonstrated promising preclinical data indicating that KRRO-121 could achieve approximately 40% editing on glutamine synthesis, potentially creating substantial market opportunities with an estimated pharmacoeconomic upside of $3.5 billion across its target indications. As Korro Bio prepares for an Investigational New Drug (IND) application and Phase 1 first-in-human study slated for the second half of 2026, the pipeline advancements and demonstrated safety profile are factors contributing to a positive outlook on the stock.
Bears say
Korro Bio's stock faces a negative outlook primarily due to the disappointing results from its KRRO-110 program, leading to a significant stock selloff, and the announcement of potential delays and risks associated with its pipeline candidates, particularly KRRO-121. There are ongoing concerns regarding the company's ability to generate favorable clinical data, which is crucial for market confidence, and potential regulatory disputes that could undermine the interpretation of clinical trial results. Furthermore, the threat of new treatment developments by competitors and possible intellectual property infringement suits could impose additional financial burdens and impact the viability of Korro Bio's therapies.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares